New Heart-Protection Use for Mounjaro in Type 2 Diabetes

Mounjaro (tirzepatide) is a once-weekly subcutaneous injection. On the US Prescribing Information (Recent Major Changes 08/2026) it is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.

This draft is about the new adult CV risk-reduction door. The sugar-control indication (including ages 10+) remains on the same USPI but is not the expansion being walked here.

This is a traditional FDA supplemental approval of a product first approved in 2022.

Distinct path — not this carton (fact-only): Zepbound (tirzepatide) for chronic weight management is a separate branded carton/indication conversation. Trulicity (dulaglutide) was the active comparator in SURPASS-CVOT — not this product. Other GLP-1 medicines with CV claims have separate labels. Today’s US labelled tirzepatide CV risk-reduction door for adults with type 2 diabetes at high CV risk is Lilly Mounjaro (NDA 215866/S-044).

The FDA approved NDA 215866/S-044 (with related S-045 dosing clarification) effective on the letter date 27 August 2026 (electronic signature Mahtab Niyyati; Lilly public announcement dated 28 August 2026). Applicant: Eli Lilly and Company, Indianapolis, IN. Letter attention: Jacob Monroe, PhD and Asavari Wagle. USPI Revised 08/2026. Reference ID on letter 5860252.

Where this is taking place

Commercial labelled door today: United States — FDA-labelled Mounjaro for adults with type 2 diabetes at high CV risk, prescribed through a diabetes / endocrinology / cardiology / primary-care clinician already able to prescribe weekly tirzepatide pens or vials, with the usual titration and safety monitoring. Existing US commercial supply and Lilly support channels apply. This is a prescription diabetes / CV-risk conversation — not a DIY import and not an obesity-only Zepbound claim.

Outside the United States: As of this draft, no confirmed Health Canada Product Monograph text, European Commission marketing authorisation, MHRA licence, TGA listing, Swissmedic authorisation, or PMDA/MHLW licence for this CV indication. Existing foreign Mounjaro licences for glycemic control, if any, are not automatically this expansion. SURPASS-CVOT sites in other countries are not a foreign CV carton. Do not import on your own.

SURPASS-CVOT — NCT04255433 — Phase 3, event-driven, multicenter, international, randomized, double-blind, active-comparator (dulaglutide 1.5 mg weekly) study. Lead framing on USPI: adults with inadequately controlled type 2 diabetes and established CV disease. CT.gov status at draft time: COMPLETED. Actual enrolment 13,299. Expanded access: CT.gov reports hasExpandedAccess: false. Locations span many countries including the United States and Canada among others. Honesty: A completed CVOT supports the label — that is not open new enrolment, and Canadian trial sites are not a Canadian CV Product Monograph.

The practical commercial door in the US is a clinician who can confirm type 2 diabetes and high CV risk, review contraindications (personal/family history of medullary thyroid carcinoma or MEN2; serious hypersensitivity), plan weekly titration, monitor gastrointestinal and retinopathy watchpoints, and arrange payer / Lilly support logistics.

Approval matrix

Access by country

• United States: Ask a diabetes / endocrinology / cardiology / primary-care clinician about FDA-labelled Mounjaro for this heart-protection door. Labelled August 2026 to reduce MACE (CV death, non-fatal MI, or non-fatal stroke) in adults with type 2 diabetes at high risk for these events. Recommended dosage family: start 2.5 mg subcutaneously once weekly; if additional glycemic control is needed, increase in 2.5 mg increments after at least 4 weeks on the current dose; maximum 15 mg once weekly. Example single-dose pen 4-packs include NDC 0002-1506-80 (2.5 mg), 0002-1495-80 (5 mg), 0002-1484-80 (7.5 mg), 0002-1471-80 (10 mg) — confirm the strength on the carton with the pharmacy. Suspected adverse reactions: Eli Lilly 1-800-LillyRx (1-800-545-5979) or FDA MedWatch 1-800-FDA-1088. No list price or copay dollars in this article. This is US commercial labelled supply, not a DIY import.

• Canada: This CV Mounjaro authorisation is not confirmed. Ask the Canadian diabetes clinic what legal paths exist in Canada when a Canadian label for this CV use is not confirmed. An existing Canadian glycemic carton, if present, is not automatically this expansion.

• European Union / United Kingdom / Australia / Japan / other countries: Regulator authorisation for this CV use is not confirmed in this draft. Completed trial sites are not a commercial foreign carton for the new use. Do not import on your own.

• If your regulator has not authorised this use: do not import on your own. Ask the local clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, or waiting — without treating a US pen as a foreign carton for this expansion.

Who is eligible (from the US label)

This is an adult type 2 diabetes + high CV risk conversation on the Prescribing Information for the new door — not a claim that Mounjaro beat dulaglutide on MACE, and not a collapse into the Zepbound obesity carton.

United States (USPI, revised August 2026):

• Indication (this draft): Reduce the risk of major adverse CV events (CV death, non-fatal MI, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
• Recommended dosage: Start 2.5 mg SC once weekly; titrate by 2.5 mg after ≥4 weeks as needed; max 15 mg weekly.
• Contraindications: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); known serious hypersensitivity to tirzepatide or excipients.
• Boxed warning: Tirzepatide causes thyroid C-cell tumors in rats; human relevance unknown; counsel on symptoms of thyroid tumors.
• Other warnings (highlights): Acute pancreatitis; hypoglycemia with insulin/secretagogues; hypersensitivity; acute kidney injury from volume depletion; severe gastrointestinal reactions (not recommended in severe gastroparesis); diabetic retinopathy complications in patients with history of diabetic retinopathy; acute gallbladder disease; pulmonary aspiration risk with anesthesia/deep sedation; never share a KwikPen between patients.
• Most common adverse reactions (≥5% on glycemic program labeling): nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain.
• Pediatrics: Glycemic control labelled for ages 10+; the CV indication text on Highlights/section 1 is written for adults.
• SURPASS-CVOT population (USPI): Adults ≥40 years with T2D and established CV disease; HbA1c 7.0–10.5%; BMI ≥25; mean age 64; mean diabetes duration 15 years; baseline CAD 65%, prior MI 47%, prior stroke 19%, heart failure history 20%.

Not labelled on sources confirmed for this draft:

• Proven superiority to dulaglutide on MACE (superiority not established).
• This CV expansion in Canada, the EU, UK, Japan, Australia, or Switzerland (not confirmed here).
• Using the Zepbound obesity brand as this T2D CV carton.
• Treating NCT04255433 as open commercial enrolment.

What the pivotal study showed (Prescribing Information)

Use the Prescribing Information for a prescription conversation. Journals are supportive reading.

SURPASS-CVOT — NCT04255433 (USPI section 14.6 / Table 10):

Noninferiority of Mounjaro to dulaglutide for MACE-3: p=0.007. Superiority to dulaglutide was not established. Median study observation time 210.1 weeks. Component and all-cause death rows were not controlled for family-wise type I error on the USPI footnote, so they are not independently proven labelled wins.

Trial-status honesty: CT.gov status COMPLETED. Labelled commercial CV door ≠ open pivotal enrolment.

How it is taken (US label — keep this exact)

Who / research team (primary sources only)

• Sponsor / applicant: Eli Lilly and Company (sNDA letter; USPI).
• Letter attention: Jacob Monroe, PhD and Asavari Wagle, Global Regulatory Affairs (NDA 215866/S-044/S-045 letter).
• Pivotal trial: SURPASS-CVOT (NCT04255433) — USPI section 14.6.
• Patient / AE contact (label): Eli Lilly and Company 1-800-LillyRx (1-800-545-5979); FDA MedWatch 1-800-FDA-1088.
• Names and phones below are limited to what appears on the Prescribing Information, FDA supplement approval letter, ClinicalTrials.gov, and clearly labelled company materials.

Sources

1. FDA — NDA 215866/S-044 and S-045 Supplement Approval Letter for Mounjaro (tirzepatide) (27 Aug 2026; Reference ID 5860252).
2. Eli Lilly — Mounjaro US Prescribing Information (Revised 08/2026), including section 14.6 SURPASS-CVOT.
3. Eli Lilly — FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk… (28 Aug 2026 announcement).
4. ClinicalTrials.gov — NCT04255433 (SURPASS-CVOT).
5. Health Canada DPD — Mounjaro DIN listings (glycemic pens; CV PM text not confirmed this draft).

Not medical advice. Talk with a clinician who knows the full history before any treatment decision. Authorized is not funded.